Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
1.520
-0.070 (-4.40%)
May 18, 2026, 4:00 PM EDT - Market closed

Indaptus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.410.498.118.768.595.21
Research & Development
7.029.347.257.626.322.52
Total Operating Expenses
17.4219.8315.3716.3814.917.73
Operating Income
-17.42-19.83-15.37-16.38-14.91-7.73
Total Non-Operating Income (Expense)
-1.44-1.020.340.960.590.02
Pretax Income
-18.86-20.85-15.02-15.42-14.32-7.71
Net Income
-18.86-20.85-15.02-15.42-14.32-7.71
Net Income to Common
-18.86-20.85-15.02-15.42-14.32-7.71
Shares Outstanding (Basic)
410000
Shares Outstanding (Diluted)
410000
Shares Change (YoY)
834.62%189.14%11.36%1.68%101.98%110.35%
EPS (Basic)
-15.40-21.58-44.96-51.24-48.44-52.92
EPS (Diluted)
-15.40-21.58-44.96-51.24-48.44-52.92
Shares Outstanding
113.242.170.430.30.30.29
Free Cash Flow
-16.79-14.82-12.32-13.41-13.08-11.29
Free Cash Flow Per Share
-4.69-15.34-36.88-44.68-44.32-77.31
EBITDA
-17.42-19.83-15.37-16.38-14.91-7.73
EBIT
-17.42-19.83-15.37-16.38-14.91-7.73
Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q